Role of Dyspnea in the Progression of Pediatric Acute Respiratory Distress Syndrome

Recruiting Observational Study
Pediatric Acute Respiratory Distress Syndrome (PARDS)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Month – 18
Sex
Any
Study type
Observational
Participants needed
68 (estimated)
Sponsor
Universidad Nacional Andres Bello · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Pediatric acute respiratory distress syndrome (ARDS) is a life-threatening clinical syndrome, and dyspnea is its key symptom. Strenuous respiratory effort is a "second hit" for ARDS lungs, inducing changes in regional lung aeration and amplifying lung damage in preclinical studies, a phenomenon known as "patient self-inflicted lung injury". In a clinical setting, clinicians are concerned about the…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1\) children younger than 18 years old; 2) diagnosis of pediatric ARDS, as defined by the 2023 Pediatric Acute Lung Injury Consensus Conference (PALICC2); and 3) consent to participate given by legal guardians. Exclusion Criteria: 1\) tracheostomy; 2) neuromuscular disease; 3)…
Contacts

Pablo Cruces, Full Professor

(56)990200810

pablo.cruces@unab.cl

CONTACT